|Day's Range||0.0500 - 0.0500|
Akerna Corp. (KERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Akerna ( NASDAQ:KERN ) First Quarter 2023 Results Key Financial Results Revenue: US$2.60m (down 63% from 1Q 2022). Net...
Akerna to sell its cannabis software business, including MJ Platform and Leaf Data Systems, to MJ Freeway Acquisition Co in a $5 million cash transaction; Alleaves participating in the financing of the acquisition; closing to coincide with previously announced Gryphon Digital Mining merger DENVER, April 28, 2023 (GLOBE NEWSWIRE) -- Akerna Corp. (“Akerna”) (Nasdaq: KERN) today announced that simultaneous to its merger with Gryphon Digital Mining, Inc. (“Gryphon”), Akerna will sell its software bu
KERN, BRDG and CAC have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2023.
Gryphon will be presenting at 12:30 pm (ET), Thursday April 27th, 2023DENVER, April 26, 2023 (GLOBE NEWSWIRE) -- Gryphon Digital Mining a private company with a leading net carbon neutral bitcoin miner with a proposed merger with Akerna Corp (NASDAQ: KERN), will present at the Ladenburg Thalmann Technology Expo 2023 in New York on April 27th at 12:30 pm ET. CEO Rob Chang will be providing an update on the proposed merger and highlight Gryphon’s industry leading operating performance. Presentatio
DENVER, April 07, 2023 (GLOBE NEWSWIRE) -- Akerna (Nasdaq: KERN), an emerging technology firm, announces that it has received an unsolicited acquisition proposal that Akerna’s Board has determined is a superior offer, from an undisclosed company, for Akerna’s software business. As a result and in accordance with their fiduciary duties, the Board approved the termination of the agreement for the sale of its software business to POSaBIT. Akerna’s Board of Directors carefully evaluated the confiden
DENVER, March 21, 2023 (GLOBE NEWSWIRE) -- Akerna (Nasdaq: KERN), an emerging technology firm, today reported its unaudited financial results for the fourth quarter, ended December 31, 2022. Key Developments: Akerna completed the sales of its 365 Cannabis and Last Call Analytics business units in January 2023 for combined consideration valued at approximately $2.9 millionAkerna announced a proposed merger with Gryphon Digital Mining and the simultaneous proposed sale of its non-enterprise softwa
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).
Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.
Investors are optimistic about Boston Scientific (BSX), led by impressive value-added acquisitions.
Bruker (BRKR) extends support to the expansion efforts of the UK Science community by providing 1.2 GHz Avance NMR spectrometers.
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
Medtronic's (MDT) Affera Mapping and Ablation System is intended to treat atrial arrhythmias.
Abbott (ABT) currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in the high-single digits in 2023.
According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
Investors are optimistic about Walgreens Boots (WBA), backed by continued partnership growth and a strong focus on strategic execution.
Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.
Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.
Syneos Health (SYNH) remains confident about the long-term strength of its business, given its robust backlog and unique market position.
Investors are optimistic about LabCorp (LH) backed by strength in its Drug Development business.
Henry Schein (HSIC) joined ASCA as part of its commitment to augment the value of ambulatory surgery centers.
Henry Schein's (HSIC) distribution business boasts a wide global footprint with 61 distribution centers.
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.